貝瑞基因(000710.SZ):君睿祺累計減持540萬股 減持數量過半
格隆匯9月23日丨貝瑞基因(000710.SZ)公佈,近日,公司收到《天津君睿祺股權投資合夥企業(有限合夥)關於股份減持進展的告知函》:君睿祺自公司披露《關於持股5%以上股東減持股份數量達1%的公告》後已累計減持公司股份數量達1%,且截至公告日,減持計劃減持數量已過半,減持計劃尚未實施完畢,其於2020年9月18日至2020年9月22日累計減持360萬股,減持比例1.0152%;於2020年9月3日至2020年9月23日累計減持540萬股,減持比例1.5228%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.